Annual CFF
$264.13 M
+$91.88 M+53.34%
31 December 2023
Summary:
Syndax Pharmaceuticals annual cash flow from financing activities is currently $264.13 million, with the most recent change of +$91.88 million (+53.34%) on 31 December 2023. During the last 3 years, it has risen by +$145.67 million (+122.96%). SNDX annual CFF is now -13.24% below its all-time high of $304.42 million, reached on 31 December 2020.SNDX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$3.10 M
+$2.42 M+358.28%
30 September 2024
Summary:
Syndax Pharmaceuticals quarterly cash flow from financing activities is currently $3.10 million, with the most recent change of +$2.42 million (+358.28%) on 30 September 2024. Over the past year, it has dropped by -$255.38 million (-98.80%). SNDX quarterly CFF is now -98.80% below its all-time high of $258.48 million, reached on 31 December 2023.SNDX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$264.43 M
+$1.25 M+0.47%
30 September 2024
Summary:
Syndax Pharmaceuticals TTM cash flow from financing activities is currently $264.43 million, with the most recent change of +$1.25 million (+0.47%) on 30 September 2024. Over the past year, it has increased by +$293.00 thousand (+0.11%). SNDX TTM CFF is now -13.14% below its all-time high of $304.42 million, reached on 31 December 2020.SNDX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SNDX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -98.8% | +0.1% |
| 3 y3 years | +123.0% | -97.2% | +123.2% |
| 5 y5 years | +824.5% | +5241.4% | +825.5% |
SNDX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +123.0% | -98.8% | +122.9% | at high | +124.0% |
| 5 y | 5 years | -13.2% | +824.5% | -98.8% | +122.9% | -13.1% | +825.5% |
| alltime | all time | -13.2% | +4526.6% | -98.8% | +122.9% | -13.1% | >+9999.0% |
Syndax Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.10 M(+358.3%) | $264.43 M(+0.5%) |
| June 2024 | - | $676.00 K(-68.8%) | $263.18 M(-0.2%) |
| Mar 2024 | - | $2.17 M(-99.2%) | $263.83 M(-0.1%) |
| Dec 2023 | $264.13 M(+53.3%) | $258.48 M(>+9900.0%) | $264.13 M(+56.2%) |
| Sept 2023 | - | $1.85 M(+39.8%) | $169.15 M(+10.0%) |
| June 2023 | - | $1.32 M(-46.5%) | $153.78 M(-11.7%) |
| Mar 2023 | - | $2.47 M(-98.5%) | $174.17 M(+1.1%) |
| Dec 2022 | $172.25 M(+45.4%) | $163.50 M(-1308.9%) | $172.25 M(+45.3%) |
| Sept 2022 | - | -$13.53 M(-162.3%) | $118.53 M(-11.4%) |
| June 2022 | - | $21.72 M(+3799.5%) | $133.76 M(+13.3%) |
| Mar 2022 | - | $557.00 K(-99.5%) | $118.06 M(-0.3%) |
| Dec 2021 | $118.46 M(-61.1%) | $109.78 M(+6338.7%) | $118.46 M(-19.6%) |
| Sept 2021 | - | $1.71 M(-71.7%) | $147.34 M(-0.0%) |
| June 2021 | - | $6.02 M(+527.1%) | $147.41 M(-41.1%) |
| Mar 2021 | - | $960.00 K(-99.3%) | $250.39 M(-17.8%) |
| Dec 2020 | $304.42 M(+965.5%) | $138.66 M(+7747.1%) | $304.42 M(+83.6%) |
| Sept 2020 | - | $1.77 M(-98.4%) | $165.82 M(+1.0%) |
| June 2020 | - | $109.00 M(+98.2%) | $164.14 M(+197.7%) |
| Mar 2020 | - | $55.00 M(>+9900.0%) | $55.14 M(+93.0%) |
| Dec 2019 | $28.57 M(+81.6%) | $58.00 K(-27.5%) | $28.57 M(-17.6%) |
| Sept 2019 | - | $80.00 K(+1233.3%) | $34.66 M(-21.3%) |
| June 2019 | - | $6000.00(-100.0%) | $44.04 M(-0.2%) |
| Mar 2019 | - | $28.43 M(+362.6%) | $44.12 M(+180.5%) |
| Dec 2018 | $15.73 M | $6.14 M(-35.1%) | $15.73 M(-55.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | $9.46 M(>+9900.0%) | $35.20 M(+31.6%) |
| June 2018 | - | $89.00 K(+169.7%) | $26.74 M(-64.6%) |
| Mar 2018 | - | $33.00 K(-99.9%) | $75.64 M(-0.1%) |
| Dec 2017 | $75.72 M(+39.7%) | $25.61 M(+2451.2%) | $75.72 M(+50.6%) |
| Sept 2017 | - | $1.00 M(-98.0%) | $50.28 M(-1.4%) |
| June 2017 | - | $48.99 M(>+9900.0%) | $50.99 M(+6513.5%) |
| Mar 2017 | - | $117.00 K(-33.5%) | $771.00 K(-98.6%) |
| Dec 2016 | $54.20 M(-29.9%) | $176.00 K(-89.7%) | $54.20 M(+20.9%) |
| Sept 2016 | - | $1.71 M(-238.8%) | $44.84 M(-56.5%) |
| June 2016 | - | -$1.23 M(-102.3%) | $103.19 M(-16.2%) |
| Mar 2016 | - | $53.55 M(-683.2%) | $123.10 M(+59.3%) |
| Dec 2015 | $77.27 M(+522.6%) | -$9.18 M(-115.3%) | $77.27 M(-14.6%) |
| Sept 2015 | - | $60.06 M(+221.6%) | $90.44 M(+126.7%) |
| June 2015 | - | $18.68 M(+142.2%) | $39.90 M(+96.3%) |
| Mar 2015 | - | $7.71 M(+93.0%) | $20.33 M(+63.8%) |
| Dec 2014 | $12.41 M(-40.6%) | $4.00 M(-58.0%) | $12.41 M(-38.8%) |
| Sept 2014 | - | $9.51 M(-1166.3%) | $20.29 M(+17.6%) |
| June 2014 | - | -$892.00 K(+337.3%) | $17.25 M(-9.9%) |
| Mar 2014 | - | -$204.00 K(-101.7%) | $19.15 M(-8.3%) |
| Dec 2013 | $20.89 M(+265.9%) | $11.88 M(+83.4%) | $20.89 M(+131.7%) |
| Sept 2013 | - | $6.47 M(+544.3%) | $9.01 M(+255.0%) |
| June 2013 | - | $1.00 M(-34.5%) | $2.54 M(+65.5%) |
| Mar 2013 | - | $1.53 M | $1.53 M |
| Dec 2012 | $5.71 M | - | - |
FAQ
- What is Syndax Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals quarterly CFF year-on-year change?
- What is Syndax Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals TTM CFF year-on-year change?
What is Syndax Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of SNDX is $264.13 M
What is the all time high annual CFF for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high annual cash flow from financing activities is $304.42 M
What is Syndax Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of SNDX is $3.10 M
What is the all time high quarterly CFF for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high quarterly cash flow from financing activities is $258.48 M
What is Syndax Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, SNDX quarterly cash flow from financing activities has changed by -$255.38 M (-98.80%)
What is Syndax Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of SNDX is $264.43 M
What is the all time high TTM CFF for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high TTM cash flow from financing activities is $304.42 M
What is Syndax Pharmaceuticals TTM CFF year-on-year change?
Over the past year, SNDX TTM cash flow from financing activities has changed by +$293.00 K (+0.11%)